Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins

A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer

(2022) Pierina Cetraro et al.   Cancers

TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma

(2022) Vivian Changying Jiang et al.   Molecular Cancer

MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas

(2021) Michelle Y. Wang et al.   Blood Cancer Journal

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

(2021) Shaojun Zhang et al.   Nature Communications

Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner

(2021) Tingting Liu et al.   CLINICAL CANCER RESEARCH

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma

(2021) Vivian Changying Jiang et al.   Journal of Hematology & Oncology

Targeting MCL-1 in hematologic malignancies: Rationale and progress

(2020) AndrewH. Wei et al.   BLOOD REVIEWS

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition

(2020) Bing Z. Carter et al.   HAEMATOLOGICA

A Delicate Balance - The BCL-2 Family and its Role in Apoptosis, Oncogenesis, and Cancer Therapeutics

(2019) Tristan Knight et al.   BIOCHEMICAL PHARMACOLOGY

BCL2 blockade overcomes MCL1 resistance in multiple myeloma

(2019) Ka Tat Siu et al.   LEUKEMIA

Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives

(2019) Hui Cong et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

(2019) Preetesh Jain et al.   AMERICAN JOURNAL OF HEMATOLOGY

Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma

(2019) Liang Zhang et al.   Science Translational Medicine

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

(2019) Romain Guièze et al.   CANCER CELL

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

(2018) Lan V. Pham et al.   CLINICAL CANCER RESEARCH

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy

(2018) Toby A. Eyre et al.   HAEMATOLOGICA

Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma

(2018) Carrie J. Li et al.   MOLECULAR CANCER THERAPEUTICS

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

(2018) Adriana E. Tron et al.   Nature Communications

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathways and mechanisms of venetoclax resistance

(2017) Prithviraj Bose et al.   LEUKEMIA & LYMPHOMA

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

(2017) Xiaohong Zhao et al.   Nature Communications

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

(2014) G. L. Kelly et al.   GENES & DEVELOPMENT

SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy

(2014) Eva Rettinger et al.   Frontiers in Pediatrics

Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration

(2012) Rhonda M. Perciavalle et al.   NATURE CELL BIOLOGY

Targeting IAP proteins for therapeutic intervention in cancer

(2012) Simone Fulda et al.   NATURE REVIEWS DRUG DISCOVERY